Eisai to start clinical trial of experimental drug for COVID-19
Japanese pharmaceutical firm Eisai Co. is set to start clinical trials in the United States of its experimental drug eritoran in the battle against coronavirus, with results potentially available by the year-end, the company said Wednesday. Eisai will test eritoran, initially developed to treat severe ...
Japanese firms take Brexit in stride but worry over British prospects for trade talks with EU
Japanese companies in Britain are taking the British exit from the European Union in stride, but some are wary that if Britain-EU trade talks falter, prospects for business in Europe will become uncertain. Many firms had already completed preparations for Britain's exit from the bloc, ...
Biogen builds case for its Alzheimer's drug, but skeptics say more data needed
Biogen Inc. laid out more data Thursday on its experimental Alzheimer's drug, raising no major safety alarms but also offering little compelling evidence that the drug, once declared a failure, actually works. Experts had been watching closely for any statistical abnormalities or excess safety issues ...
Japanese manufacturers are growing frustrated yet again over another delay in Britain's withdrawal from the European Union, as the prolonged confusion is raising concerns over disruptions to their businesses and supply chains. Britain is expected to postpone their withdrawal from the union, previously slated for ...
Biogen and Eisai revive plans for Alzheimer's drug aducanumab, but prospects still shaky
Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer's treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decline of patients. The drugmaker's shares soared 27 percent in New York trading, recouping almost ...
Japan's Eisai agrees with U.S.-based Merck on potential $5.76 billion cancer drugs deal
Eisai Co. and U.S.-based Merck & Co. said Thursday they have agreed to jointly develop cancer drugs for global sales, with the Japanese pharmaceutical firm potentially receiving up to $5.76 billion if it proves a success. The firms said they will initiate new clinical studies ...
Pill-popping is a business worth watching for Japan's drugmakers
To eke out growth in one of the developed world's most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers. Medication adherence is seen as an impediment to health as well as sales in Japan, and companies including Otsuka Pharmaceutical ...
Just days after Biogen Inc. revealed promising early data from an experimental Alzheimer's treatment, new research from the Mayo Clinic may revive a long-running debate over whether the drug industry is focusing on the right target in developing therapies to treat the disease. The study, ...
